BHARAT BIOTECH INTERNATIONAL LIMITED

Bharat Biotech and GSK announced they will reduce the price of the world's first malaria vaccine RTS,S by more than half to less than $5 per dose by 2028.

Bharat Biotech's oral cholera vaccine Hillchol has demonstrated non-inferiority against both Ogawa and Inaba serotypes in Phase III clinical trials involving 1,800 participants across India.

Biovet, a subsidiary of Bharat Biotech, has launched Biolumpivaxin, the world's first DIVA marker vaccine to protect livestock from Lumpy Skin Disease, which caused over 200,000 cattle deaths in India.

Bharat Biotech has launched India's first integrated Cell and Gene Therapy facility in Hyderabad with a $75 million investment, expanding beyond its core vaccine business into advanced therapeutics.

Biovet, a Bharat Biotech group company, has received CDSCO approval for Biolumpivaxin, the world's first DIVA-marker vaccine for Lumpy Skin Disease in cattle and buffaloes.

FDA approves Ocugen's investigational new drug application for a nasal COVID-19 vaccine, developed at Washington University in St. Louis, advancing to Phase 1 clinical trials this spring.

ICMR is conducting a major clinical trial testing BCG vaccine in vulnerable adult populations, with approximately 100 million people receiving the vaccine as part of the study.

Bharat BioTech's COVAXIN, developed with the National Institute of Virology, initiates Phase 1 clinical trials involving 375 participants to assess safety and efficacy.

• ICMR has formalized agreements with multiple sponsors to advance four promising molecules into first-in-human clinical trials, marking a significant step for pharmaceutical innovation in India. • The collaborations include research into a small molecule for multiple myeloma, a Zika vaccine, a seasonal influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukemia. • This initiative aims to establish India as a leader in the clinical development of pharmaceutical agents through strategic public-private partnerships, enhancing the nation's capacity for early-phase clinical trials. • The ICMR Network for phase 1 clinical trials includes four institutions across India, supported by a central coordinating unit, to ensure smooth and effective trial operations.

• The Indian Council of Medical Research (ICMR) has signed agreements to advance first-in-human Phase 1 clinical trials for four molecules. • Collaborations include research for multiple myeloma, Zika vaccine development, influenza vaccine trials, and CAR-T cell therapy advancements. • This initiative aims to establish India as a leader in pharmaceutical clinical development and affordable healthcare solutions. • The ICMR network includes four institutions across India, enhancing the capacity for early-phase clinical trials with robust infrastructure.